Literature DB >> 1904455

Red cell aplasia in myelodysplastic syndrome.

P J Williamson1, D G Oscier, A J Bell, T J Hamblin.   

Abstract

Six cases of red cell aplasia occurring in patients with myelodysplastic syndromes (MDS) showed a diversity of clinical course and prognosis. In some patients red cell aplasia may have represented an evolution of MDS while in others autoimmune destruction of erythoblasts may have been the mechanism. A proliferative phase is seen in many of these patients, the clinical importance of which is uncertain.

Entities:  

Mesh：

Year:  1991        PMID： 1904455      PMCID： PMC496880          DOI： 10.1136/jcp.44.5.431

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  9 in total

Review 1.  Acquired pure red cell aplasia.

Authors:  S S Ammus; A A Yunis
Journal:  Am J Hematol       Date:  1987-03       Impact factor: 10.047

2.  Red cell hypoplasia associated with myeloproliferative and myelodysplastic syndrome.

Authors:  M K Cook
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

3.  Pure red cell aplasia associated with chronic myelomonocytic leukaemia.

Authors:  A López-Guillermo; F Cervantes; E Sacanella; L Florensa; C Rozman
Journal:  Clin Lab Haematol       Date:  1989

4.  Pure red cell aplasia heralding chronic myelomonocytic leukaemia.

Authors:  P H Bolton-Maggs; M J Galloway; E G Rhodes
Journal:  Clin Lab Haematol       Date:  1989

5.  The 5a-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands.

Authors:  H Kerkhofs; A Hagemeijer; C H Leeksma; J Abels; G J den Ottolander; R Somers; W B Gerrits; M M Langenhuiÿen; A E von dem Borne; J O Van Hemel; J P Geraedts
Journal:  Br J Haematol       Date:  1982-11       Impact factor: 6.998

6.  Red cell hypoplasia, thrombocytosis, and leucocytosis: myelodysplastic and proliferative syndrome.

Authors:  A Craig; C G Geary; E M Love; J Liu-Yin
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

7.  Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies.

Authors:  G J Mufti; A Figes; T J Hamblin; D G Oscier; J A Copplestone
Journal:  Br J Haematol       Date:  1986-05       Impact factor: 6.998

8.  Red cell aplasia and chronic granulocytic leukaemia.

Authors:  E N Dessypris; C L McKee; C Metzantonakis; M Teliacos; S B Krantz
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

9.  Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.

Authors:  D G Oscier; A Worsley; S Darlow; A Figes; J D Williams; T J Hamblin
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156
  9 in total
  11 in total

1.  Defective erythropoiesis in myelodysplastic syndromes.

Authors:  W N Patton; C M Bunce; G Brown; S Larkin
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

2.  Myelodysplastic syndrome with erythroid hypoplasia.

Authors:  R Goyal; N Varma; R K Marwaha
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

3.  DNA Methyl Transferase 3A (DNMT3A) Mutation Presenting as Isolated Pure Red Cell Aplasia.

Authors:  Adarsh Sidda; Gurusidda Manu; Mohamed Alsharedi; Jennifer Dotson; Niru Nahar
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

4.  Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy.

Authors:  Takahiro Yamauchi; Haruhisa Shirasaki; Atsushi Kuwata; Taro Yamashita; Shin Imamura; Hiroshi Tsutani; Takanori Ueda
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

Review 5.  Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review.

Authors:  Masao Ogata; Eiichi Ohtsuka; Tomoyuki Imamura; Junji Ikewaki; Yuko Ogata; Kazuhiro Kohno; Toshiyuki Nakayama; Keiji Ono; Yoshio Saburi; Hiroshi Kikuchi; Masaru Nasu
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

6.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

7.  Myelodysplastic syndrome with erythroid aplasia following pure red cell aplasia.

Authors:  Hyoung Doo Kim; Kee Won Kim; Suk Young Park; Hyeok Jae Ko; Young Yong An; So Young Shin; Ji Young Jang
Journal:  Korean J Intern Med       Date:  2004-09       Impact factor: 2.884

8.  A case of relapsing polychondritis associated with myelodysplastic syndrome with erythroid hypoplasia/aplasia.

Authors:  Seong-Wook Heo; Kyu-Hyun Cho; Jung-Il Ryu; Seung-Hie Chung; Chae-Gi Kim; Sang-Gyung Kim; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

9.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

10.  Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.

Authors:  Anh Khoi Vo; Hilde Kollsete Gjelberg; Randi Hovland; Marte Karen Lindstad Brattås; Øystein Bruserud; Håkon Reikvam
Journal:  Case Rep Hematol       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.